Welcome to our dedicated page for PLIANT THERAPEUTICS SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pliant Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing integrin-based therapeutics. Recent 8-K reports cover quarterly financial results, corporate updates for the PLN-101095 oncology program, material agreements, at-the-market equity offering arrangements, and amendments to the company’s stockholder rights agreement and Series A Junior Participating Preferred Purchase Rights.
Proxy and governance filings describe board composition, director retirements, committee roles, executive compensation, equity awards, and stockholder voting matters. Other material-event reports record officer appointments or departures and changes affecting security-holder rights, connecting the company’s capital structure and governance disclosures to its clinical-stage operating model.
Pliant Therapeutics, Inc. director Robert Iannone filed an initial statement of beneficial ownership on Form 3. The structured data shows no reported purchases, sales, derivative exercises, gifts, tax withholdings, or other transactions in this filing.
PLIANT THERAPEUTICS, INC. director Robert Iannone received a grant of 60,000 stock options on July 9, 2026. The options have an exercise price of $1.13 per share and are exercisable for common stock until July 9, 2036. According to the vesting terms, 1/36th of the options vest in substantially equal monthly installments on each monthly anniversary of July 9, 2026, conditioned on Iannone’s continuous service to the company.
Pliant Therapeutics, Inc. director Borellini Flavia has filed an initial statement of beneficial ownership as a reporting person. The filing lists her status as a director of the company and reports no equity transactions or derivative positions, providing an initial disclosure of her insider status without detailing current holdings.
PLIANT THERAPEUTICS, INC. director Flavia Borellini received a compensatory stock option grant covering 60,000 shares of common stock on July 9, 2026. The option has an exercise price of $1.13 per share and expires on July 9, 2036. Vesting occurs as 1/36th of the option each month starting on July 9, 2026, subject to her continued service, and all 60,000 option shares are reported as held directly after the award.
Pliant Therapeutics, Inc. expanded its Board of Directors from seven to nine members effective July 9, 2026, and appointed Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director to fill the new seats. Both have been determined to be independent directors under SEC and Nasdaq rules. Dr. Iannone joins the Research and Development Committee, while Dr. Borellini becomes its chairperson. Each new director will receive an annual cash retainer of $40,000, pro-rated for partial service periods; Dr. Iannone will receive an additional $7,500 for R&D Committee membership and Dr. Borellini $15,000 for serving as R&D Committee chair. On the effective date, each was granted an option to purchase 60,000 shares of common stock, vesting in substantially equal monthly installments over three years, subject to continued Board service. The company also entered into its standard indemnification agreements with both directors.
Pliant Therapeutics director Gayle A. Crowell received a compensation grant of stock options. The award covers 70,000 options to buy Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.
According to the vesting schedule, 25% of the options vest on October 1, 2026, another 25% on January 1, 2027, and another 25% on April 1, 2027. The remaining 25% vest on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to Crowell’s continued service as a director.
Pliant Therapeutics director Thomas A. McCourt received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $1.14 per share and expire on June 11, 2036.
These options were granted as compensation and do not represent an open-market purchase. According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to McCourt’s continued service on the board.
Pliant Therapeutics director Steve E. Krognes received a compensation-related stock option grant. He was awarded options to purchase 70,000 shares of Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.
According to the vesting schedule, 25% of the option vests and becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, provided he continues to serve as a director through the applicable dates.
Pliant Therapeutics director John T. Curnutte received a grant of stock options covering 70,000 shares of common stock. The options carry an exercise price of $1.14 per share and expire on June 11, 2036, giving him the right to buy shares at that price in the future.
According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, subject to his continued service as a director.
PLIANT THERAPEUTICS director Hoyoung Huh received a new stock option grant for 70,000 shares of common stock. The option has a $1.14 per share exercise price and expires on June 11, 2036. This is a compensation-related award, not an open-market trade.
According to the vesting schedule, 25% of the option becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, contingent on continued board service.